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Abstract
Objective: To compare four haemoglobin measurement methods in whole blood donors.
Background: To safeguard donors, blood services measure haemoglobin concentra-
tion in advance of each donation. NHS Blood and Transplant's (NHSBT) customary
method have been capillary gravimetry (copper sulphate), followed by venous spec-
trophotometry (HemoCue) for donors failing gravimetry. However, NHSBT's custom-
ary method results in 10% of donors being inappropriately bled (ie, with haemoglobin
values below the regulatory threshold).
Methods: We compared the following four methods in 21 840 blood donors (aged
≥18 years) recruited from 10 NHSBT centres in England, with the Sysmex XN-2000
haematology analyser, the reference standard: (1) NHSBT's customary method;
(2) “post donation” approach, that is, estimating current haemoglobin concentration
from that measured by a haematology analyser at a donor's most recent prior dona-
tion; (3) “portable haemoglobinometry” (using capillary HemoCue); (4) non-invasive
spectrometry (using MBR Haemospect or Orsense NMB200). We assessed
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sensitivity; specificity; proportion who would have been inappropriately bled, or
rejected from donation (“deferred”) incorrectly; and test preference.
Results: Compared with the reference standard, the methods ranged in test sensitivity
from 17.0% (MBR Haemospect) to 79.0% (portable haemoglobinometry) in men, and
from 19.0% (MBR Haemospect) to 82.8% (portable haemoglobinometry) in women. For
specificity, the methods ranged from 87.2% (MBR Haemospect) to 99.9% (NHSBT's
customary method) in men, and from 74.1% (Orsense NMB200) to 99.8% (NHSBT's
customary method) in women. The proportion of donors who would have been inap-
propriately bled ranged from 2.2% in men for portable haemoglobinometry to 18.9% in
women for MBR Haemospect. The proportion of donors who would have been
deferred incorrectly with haemoglobin concentration above the minimum threshold
ranged from 0.1% in men for NHSBT's customary method to 20.3% in women for
OrSense. Most donors preferred non-invasive spectrometry.
Conclusion: In the largest study reporting head-to-head comparisons of four
methods to measure haemoglobin prior to blood donation, our results support
replacement of NHSBT's customary method with portable haemoglobinometry.
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1 | INTRODUCTION
Blood services are mandated to measure haemoglobin concentra-
tions of potential whole blood donors in advance of each donation.
The rationale is to protect the health of donors (ie, to prevent collec-
tion from anaemic donors and mitigate the possibilities of rendering
the donor anaemic) as well as to ensure the quality of blood prod-
ucts.1,2 European legislation on selection criteria of blood donors
(EU directive 2004/33/EC Article 4) states that haemoglobin con-
centration should be ≥125 g/L for women and ≥ 135 g/L for men
before allowing blood donation.3 There is, however, substantial vari-
ation across national blood services in methods of haemoglobin
measurement.4,5 This has resulted in part because the timing of
blood sampling and sample material for assessing blood donors is
not defined by legislation, and partly because there is little evidence
about the comparative performance of different rapid measurement
methods.6-11
The customary approach of National Health Service Blood and Trans-
plant (NHSBT, the national blood service of England) has been a gravimet-
ric method (copper sulphate test) carried out on finger-prick capillary
blood taken immediately before donation, followed by a spectrophoto-
metric test (HemoCue) with venous blood for those who fail the copper
sulphate test.12 Recent data, however, indicate that NHSBT's customary
method may allow about 10% of donors to give blood despite having
baseline haemoglobin concentrations below the minimum regulatory
threshold.13,14 By contrast, blood services in some countries (eg, the Neth-
erlands and Finland) assess haemoglobin concentration before blood
donation using a spectrophotometric test on capillary blood obtained by a
finger-prick.4 Other services (eg, France and Denmark) use haemoglobin
values obtained from the most recent prior donation (“post donation”
approach), employing automated haematology analysers of venous
blood.4,15 Other services (eg, Bavaria, Ireland, Spain) have employed non-
invasive spectrometry that does not require obtaining a blood sample.4,16
We conducted a within-person comparison of four haemoglobin
measurement methods using performance metrics relevant to the
blood donation context and comparing each method to the reference
standard of a haematology analyser.
2 | METHODS
2.1 | Study design
This study evaluated four haemoglobin measurement approaches
used by blood services in high-income countries (see “Diagnostic
tests” below) against a haematology analyser reference standard.
The study involved participant recruitment into two stages
(Figure 1). Stage 1 involved direct comparisons of invasive and
non-invasive methods in the same participants. Stage 2 involved
an indirect comparison of two non-invasive spectrometry devices
described below. Allocation of the non-invasive device between
teams was done by “cross-over” randomisation. Participants in
Stage 1 were not eligible to join Stage 2. The study protocol is
provided in the Annex. The study was registered with ISRCTN
(ISRCTN90871183), and approved by the National Research Ethics
Service (15/EE/0335).
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2.2 | Diagnostic tests
We used haemoglobin concentration measured by a Sysmex XN-
2000 haematology analyser at a central laboratory (UK BioCentre,
Milton Keynes, UK) as the study's reference standard.17 We evaluated
four rapid diagnostic tests against that standard: (1) gravimetry/
venous HemoCue (“NHSBT's customary method” at the time of this
study), i.e., a copper sulphate gravimetric test carried out on finger-
prick capillary blood, followed by spectrophotometry (HemoCue AB,
Ängelholm, Sweden) on venous blood for those failing gravimetry12;
(2) “post donation” approach, that is, estimating current haemoglobin
concentration from that measured by a haematology analyser at a
donor's most recent prior donation (ie, about 12–16 weeks earlier);
(3) “portable haemoglobinometry”, using a Hemocue 301 device using
finger-prick capillary blood18; and (4) one of two hand-held non-
invasive spectrometer devices - the MBR Haemospect (MBR Optical
Systems GmbH & Co. KG, Wuppertal, Germany)19 or the Orsense
NMB200 (OrSense Ltd, Petah-Tikva, Israel).20
2.3 | Study participants
Between February 2016 and March 2017, donors were eligible for
recruitment into COMPARE if they: were aged 18 years or older; ful-
filled routine criteria for donation (with the exception of pre-donation
haemoglobin concentration measured using the NHSBT testing
method); had an email address and access to the internet to respond
to web-based questionnaires; and were willing to undergo additional
haemoglobin concentration measurements at one of the 10 “mobile”
donor centres of NHSBT, the sole blood provider to the NHS in
England, UK. After reading study information leaflets and participating
in a discussion with donor carer staff, eligible donors were asked to
complete the study consent form and provide a blood sample. Soon
after enrolment, participants received online health and lifestyle ques-
tionnaires, including the Fitzpatrick Skin Score.21
2.4 | Outcomes
The primary endpoint was the proportion of donors in the study who
would have been inappropriately bled by each method (ie, the propor-
tion of donors for whom a given method would not identify them as
having sub-threshold haemoglobin levels as measured by the refer-
ence standard). Secondary endpoints included sensitivity, specificity,
the proportion of donors who would have been excluded from blood
donation (“deferred”) incorrectly, variability of the performance of dif-
ferent methods by donors' personal characteristics (eg, repeat vs first-
time donor, and skin colour tone), and the acceptability of different
methods according to donors.
2.5 | Statistical analysis
The statistical analysis followed a prespecified plan. Briefly, Bland-
Altman22 plots were used to assess systematic difference between
haemoglobin screening methods when compared against the refer-
ence standard, and supplemented by linear regression models to
examine proportional biases (ie, how much the difference between
F IGURE 1 CONSORT flowchart showing.
Note: 30% drop-out rate expected between Stage 1 visit 1 and visit two donors as per study design
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two methods is dependent on the magnitude of the measurement).
The percentage of donors who would have been bled below the
threshold (ie, <125 g/L for women and <135 g/L for men) was cal-
culated by taking the number of donors categorised as having ade-
quate haemoglobin levels by the screening method but should
have been deferred according to the reference standard, and divid-
ing by the total number of donors in the analysis population. The
proportion of donors incorrectly deferred above the threshold was
calculated similarly. Differences between each screening method
and the reference standard were assessed using a McNemar's test
for paired within-person comparisons. For direct comparisons
between strategies, donation outcomes were standardised by sex
and haemoglobin level to a reference population (ie, returning
Stage 1 donor population). Each observation was assigned a weight
based on the relative frequency of the sex-specific haemoglobin
level appearing in the reference population relative to the estima-
tion sample. The proportions for each of the four donation out-
comes (bled below haemoglobin threshold, bled above
haemoglobin threshold, deferred below haemoglobin threshold,
deferred above haemoglobin threshold) were then weighted
accordingly. Sensitivity (the probability of correctly identifying
donors with a low haemoglobin level) and specificity (the probabil-
ity of correctly identifying donors with sufficient haemoglobin
levels) of each screening method were calculated and used to
define the area under a receiver operating characteristic curve
(AUC) to illustrate the diagnostic ability (ie, how well a test dis-
criminates between donors with low and sufficient haemoglobin
levels) of a screening method at different haemoglobin thresholds.
Sex-specific sample size was estimated to provide 80% power, at a
5% significance level, to detect a 10% relative difference in the
false pass rate (ie, percentage of donors who would have been
bled below the threshold) between the NHSBT customary method
and any of the other tests (Annex). Analyses were conducted sepa-
rately for men and women using Stata v14. The analysis adhered
to the Standards for Reporting Diagnostic Accuracy Studies
(STARD).23
F IGURE 2 Bland–Altman plot of each haemoglobin testing strategy by sex using venous haemoglobin values as the reference test.
Note: Dotted light grey lines represent zero bias. Solid red lines represent the mean bias of the testing strategy (middle) and accompanying 95%
limit of agreement (LOA; upper and lower) of the mean bias. Dashed blue lines depict proportional bias estimated using linear regression. Men—
Post-donation strategy: N = 5920, 4.3% outside the LOA. Capillary HemoCue: N = 5279, 5.1% outside the LOA. OrSense: N = 4861, 5.7% outside
the LOA. Haemospect: N = 4352, 5.5% outside the LOA. Women - Post-donation strategy: N = 6394, 5.2% outside the LOA. Capillary HemoCue:
N = 5724, 5.0% outside the LOA. OrSense: N = 5580, 5.2% outside the LOA. Haemospect: N = 4170, 5.5% outside the LOA [Color figure can be
viewed at wileyonlinelibrary.com]
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2.6 | Role of the funding source
The academic investigators and representatives of NHSBT, a funder
of the study, participated in the study design and oversight. The inves-
tigators at the study's academic coordinating centre had sole access
to the study database, and had final responsibility for data collection,
data integrity, data analysis, and data interpretation, as well as manu-
script drafting and the decision to submit the manuscript for publica-
tion. All authors gave approval to submit for publication.
3 | RESULTS
A total of 29 029 participants were consented to participate in the
COMPARE study (17 861 in Stage 1 and 11 168 in Stage 2), of whom
21 840 (75.2%) provided data for the current analysis (Figure 1). Table
S1 shows baseline characteristics of the participants. Compared with
NHSBT's general donor population, participants were, on average,
older, more likely to be male, less ethnically diverse, and had a longer
donation career (Tables S2 and S3). Baseline characteristics were simi-
lar between participants recruited in Stages 1 and 2, although
haemoglobin concentration was approximately 3-4 g/L lower in
returning donors.
Figure 2 and Figure S1 show the mean and proportional biases
between the haemoglobin readings of each test and the reference
standard. On average, the “post donation” approach over-estimated
haemoglobin values by 3.6 g/L (95% limit of agreement −10.4, 17.6;
SD 7.1) and 4.0 g/L (−9.9, 18.0; SD 7.1) for men and women, respec-
tively, while each of the other methods tended to under-estimate
haemoglobin values; −3.1 (−18.0, 11.8; SD 7.6) and −2.4 (−16.9,
12.1; SD 7.4) g/L for portable haemoglobinometry, −4.2 (−27.3, 18.8;
SD 11.7) and −2.2 (−30.5, 26.2; SD 14.5) g/L for OrSense and −6.3
(−30.7, 18.0; SD 12.4) g/L for Haemospect. There was evidence of
proportional bias for each test, with the “post donation” approach
and Haemospect over-estimating, and portable haemoglobinometry
and OrSense underestimating haemoglobin levels at the lower end of
the distribution. Mean biases for non-invasive devices were larger in
donors recruited in Stage 2 (Figure S2). Figures 3 and S3 show sca-
tterplots of haemoglobin concentration measured by each testing
method against the reference standard.
Figure 4 shows the AUC for each test by sex. Portable
haemoglobinometry had the highest AUC, for both men and women,
across all haemoglobin thresholds examined, followed by the “post
donation” approach, the OrSense, and Haemospect. The sensitivities
of the different methods at minimum donation thresholds for men
and women were 26.0% and 34.7% for NHSBT's customary method,
27.9% and 35.5% for the “post donation” approach, 79.0% and 82.8%
for portable haemoglobinometry, 44.4% and 51.3% for OrSense, and
17.0% and 19.0% for Haemospect The specificity of each method at
the same haemoglobin thresholds for men and women were 99.9%
and 99.8%, respectively, for NHSBT's customary method, 98.8% and
96.6% for the “post donation” strategy, 87.6% and 82.1% for portable
F IGURE 3 Scatterplot comparing testing device haemoglobin values to those obtained from venous blood samples by sex [Color figure can
be viewed at wileyonlinelibrary.com]
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haemoglobinometry, 87.9% and 74.1% for OrSense, and 87.2% for
both sexes with Haemospect (Figure S4).
The prevalence of donors who would have been inappropriately bled
ranged from 2.2% in men for portable haemoglobinometry to 18.9% in
women for MBR Haemospect (Figure 5 and Table S4). Compared to
NHSBT's customary method, use of portable haemoglobinometry per-
formed best in reducing the prevalence of inappropriate bleeding (−5.6%,
−6.3, −4.9 for men and −11.1%, −11.9, −10.2 for women,
P < 0.0001 for both: Figure 6). The proportion of donors who would
have been deferred with haemoglobin concentrations above the
threshold ranged from 0.1% in men for NHSBT's customary method
to 20.8% in women for OrSense (Figure 5 and Table S4). In a sensi-
tivity analysis, the proportion of donors who would have been bled
with haemoglobin concentrations below the minimum threshold
using the “post donation” approach decreased while the number of
donors inappropriately deferred somewhat increased with longer
time between donation (Figure S5). There were notable differences
in the accuracy of methods between white and non-white donors,
especially for the non-invasive devices (Figure S6). Stage 1 donors
lost to follow-up tended to be on average younger, earlier in their
donation career, and more likely to have had haemoglobin values
beneath the threshold at their first visit (Table S6).
Regarding test acceptability, 72% of donors preferred the non-
invasive devices, 20% preferred the finger-prick test, and 8% the
“post donation” approach. However, 77% of donors reported that test
accuracy was their most important consideration.
4 | DISCUSSION
In a study of over 21 000 whole blood donors in NHSBT, the national
blood service of England, we conducted head-to-head comparisons of
four rapid methods for the measurement of pre-donation
haemoglobin levels, comparing each against the reference standard of
a haematology analyser. Our key finding was that portable
haemoglobinometry (ie, using the capillary HemoCue) had the highest
accuracy across all haemoglobin thresholds examined for both men
and women, as well as the smallest biases in comparison with the ref-
erence standard. Furthermore, pre-specified subgroup analyses indi-
cated that portable haemoglobinometry performed similarly well
among donors of different ages, ethnicities, and levels of blood dona-
tion experience. When compared to NHSBT's customary method (ie,
gravimetry/venous HemoCue), use of portable haemoglobinometry
reduced the prevalence of inappropriately bled donors, but increased
F IGURE 4 Receiver operating characteristic curves for each haemoglobin testing strategy at different haemoglobin thresholds by sex.
Note: Threshold values are shown in g/L. Sensitivity and specificity of NHSBT method has been superimposed as it only provides a pass/fail result
rather than a quantitative readout [Color figure can be viewed at wileyonlinelibrary.com]
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the proportion of donors incorrectly deferred (deferrals are disadvan-
tageous because they demotivate donors and are costly for blood
services24).
Based on these results, we offered two policies to NHSBT to
improve its current haemoglobin screening practices. First, wholesale
replacement of NHSBT's customary method with portable
haemoglobinometry alone. We estimated that when projected across
the approximately 1.4 million blood donations taking place annually in
England, this policy would prevent about 65 000 donors annually
from avoidable anaemia and potential iron deficiency and its potential
F IGURE 5 Donation outcomes by testing strategy and sex, per 100 donations standardised to the returning donor population in the
COMPARE study.
Note: †1 in every 1000 donations for men, and 2 in every 1000 donations for women are incorrectly deferred using the customary NHSBT
method [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 6 Percentage difference (95% confidence interval) in donors who would be bled below and deferred above the donation
haemoglobin threshold for each testing strategy compared with the standard NHSBT test by sex.
Note: P-values calculated using McNemar's test
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consequences. A second approach would be to use portable
haemoglobinometry only in donors who failed a more methodologi-
cally rigorous use of the gravimetric test. NHSBT estimated that this
second approach would prevent about 30 000 donors annually from
experiencing anaemia and potential iron deficiency. The second
approach would avoid the higher rates of inappropriate deferrals of
donors associated with the first approach. In 2018, NHSBT adopted
the second approach as national policy, implementing it swiftly across
the whole of the blood service of England.25,26
We made several additional observations relevant to the poli-
cies and practices of blood services. We found that the “post dona-
tion” approach (ie, estimating current haemoglobin concentration
from that measured by a haematology analyser at a donor's most
recent prior donation) performed similarly to NHSBT's customary
method when the interval between donations was about
12–16 weeks. However, the performance of this approach improved
somewhat with longer intervals between donations, and when
higher haemoglobin concentration at the first study visit was used
to predict the donor's haemoglobin concentration at the next study
visit. Blood services in several countries (eg, France, Denmark and
Germany) have recently adopted the “post donation” approach due
to its practical advantages, that is, it replaces the need for rapid on-
site testing by using a haematology analyser at a central laboratory
to measure venous blood taken from the donor's sample
pouch.15,27,28 Some blood services have started to supplement a
post-donation approach with monitoring of serum ferritin, a mea-
sure of the body's iron stores, in selected blood donors.29-31 Future
work will seek to investigate the safety, cost-effectiveness, and
practicability of the “post donation” approach in large, high-
throughput blood services such as in England.
A further finding of our study was that non-invasive spectrometry
devices (ie, MBR Haemospect and Orsense NMB200) did not generally
perform well compared with the other methods, despite their obvious
advantage of avoiding the need to take a blood sample. For example,
these methods showed lower sensitivity for detection of haemoglobin
concentration below the threshold for donation than portable
haemoglobinometry, meaning higher numbers of donors would be inap-
propriately bled. Furthermore, non-invasive spectrometry devices,
which measure haemoglobin by shining light on the skin of donors, per-
formed inconsistently in people of different ethnicities and skin colour
types, limiting the test's potential applicability to blood services in coun-
tries with a large and ethnically diverse pool of donors such as in the
UK. Some blood services have suffered adverse consequences from
introducing non-invasive spectrometry without such robust assess-
ment.16 Our study showed estimates of haemoglobin concentration by
non-invasive methods, which would result in higher levels of inappro-
priate bleeding and/or higher levels of inappropriate deferral in blood
donors when compared with portable haemoglobinometry. Neverthe-
less, further efforts are warranted to improve the performance of non-
invasive spectrometry devices, given their potential to enhance the
experience of blood donation by avoiding pain.
The current study had major strengths. It involved large numbers
of participants, providing excellent statistical power and detailed
comparisons of important sub-populations (eg, sex-specific results).
The study design was a within-person comparison, enhancing validity
by providing head-to-head comparisons of different methods to mea-
sure haemoglobin concentrations. It involved evaluation of four
methods, making it wider in scope than previous efforts focusing on
fewer methods.7,9,32-34 It used a state-of-the-art haematology ana-
lyser in an accredited central laboratory as the reference standard.
The study was embedded in NHSBT's routine blood service, enabling
rapid recruitment of blood donors and resulting in findings of direct
relevance to UK blood services.
Our study also had potential limitations. First, only about
three-quarters of participants initially consented into the study ret-
urned for the second visit to allow measurements of haemoglobin
concentration for the study purpose; however, a non-attendance
rate of 30% at the second visit was originally factored into power
calculations. Second, compared to the national donor population in
England, participants in the study were older, more likely to be
male, less ethnically diverse, and had a longer blood donation
career. Hence, some caution is needed in extrapolating the find-
ings to the general population of blood donors. Third, when
assessing the post-donation approach we invited participants for a
second visit about 12–16 weeks later, meaning our study had lim-
ited ability to assess this method for longer inter-donation inter-
vals. Fourth, the study recruited only a limited number of non-
white participants and relied on self-reported information for skin
colour tone, limiting ability to assess potential differences by eth-
nic background.
In summary, in the largest study reporting head-to-head compari-
sons of four methods to measure haemoglobin prior to blood dona-
tion, our results support replacement of NHSBT's customary method
with portable haemoglobinometry.
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